Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37544 | 0.98 | HDAC1 (0.39) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Hydrochloric Acid SCHEMBL20590135 | 0.95 | HDAC1 (0.37) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| Maleic Acid SCHEMBL28227364 | 0.84 | HCAR2 (0.40) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL420985 | 0.84 | TP53 (0.42) | TDP1CYP3A4TSHRCA1CA2 | |
| SCHEMBL27731097 | 0.83 | TP53 (0.47) | CA1CA2TP53FDPS | |
| SCHEMBL22361234 | 0.83 | TSHR (0.46) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL419967 | 0.82 | TP53 (0.50) | CA1TP53FDPSRECQL | |
| SCHEMBL10569914 | 0.81 | CA1 (0.39) | HDAC1HDAC2CHRM1AKR1A1CHRM3 | |
| SCHEMBL754167 | 0.80 | TP53 (0.48) | CA1CA2TP53FDPS | |
| SCHEMBL754171 | 0.80 | TP53 (0.48) | CA1CA2TP53FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633609-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Global Life Sciences Solutions Canada ULC (CA) | 2025-10-22 | — | — | EP | claimed |
| EP-4512475-A2 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3651734-B1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024126423-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Precision NanoSystems ULC (CA) | 2024-06-20 | — | — | WO | claimed |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | ALDEYRA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | claimed |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | claimed |
| CN-117982682-A | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-03-21 | — | — | US | claimed |
| CN-111093627-B | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-03-08 | — | — | CN | claimed |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | claimed |
| EP-1819350-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1819227-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006071491-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SUPERGEN, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060128653-A1 | Pharmaceutical formulation of decitabine | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006063111-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060128654-A1 | Pharmaceutical formulation of cytidine analogs and derivatives | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1348432-A1 | CYCLODEXTRIN-CONTAINING PHARMACEUTICAL PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6596706-B1 | For the treatment of circulatory diseases cerebral diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | CTDSP1, RNGTT, POLRMT | HDAC1 126/4885HDAC2 307/4885CHRM1 4756/4885 |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6H, PDE6D | HDAC1 2580/4885HDAC2 2755/4885CHRM1 2181/4885 |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | CTDSP1, RNGTT, POLRMT | HDAC1 126/4885HDAC2 307/4885CHRM1 4756/4885 |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, RNMT | HDAC1 2355/4885HDAC2 3733/4885CHRM1 76/4885 |
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | SLCO2B1, RPS27L, SEC23IP | HDAC1 4304/4885HDAC2 3680/4885CHRM1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.